Marshall Wace Asia’s Vertex Pharmaceuticals VRTX Stock Holding History

Marshall Wace Asia’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-81	Closed	-$15K	–	139
2019 Q1	$15K	Buy	+81	New	+$15K	﹤0.01%	85

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Marshall Wace Asia's VRTX Position: Q2 2019 in Review

Marshall Wace Asia sold out of Vertex Pharmaceuticals (VRTX) in Q2 2019, closing a stake of 81 shares — an estimated $15K sold.

Marshall Wace Asia first reported a position in VRTX in Q1 2019 and held it in 1 quarter. The position peaked at $15K in Q1 2019. 716 funds tracked by Wall St. Rank hold VRTX as of Q2 2019.

Marshall Wace Asia reported no remaining Vertex Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Marshall Wace Asia sold 81 Vertex Pharmaceuticals shares in Q2 2019, an estimated $15K.
Marshall Wace Asia first reported a position in Vertex Pharmaceuticals in Q1 2019 and held it in 1 quarter.
Marshall Wace Asia's Vertex Pharmaceuticals position peaked at $15K in Q1 2019.
716 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2019.

Based on Marshall Wace Asia's 13F filing for Q2 2019, filed 14 Aug 2019.